Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02680587 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Body Radiation for Prostate Oligometastases
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02680587 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 80 participants.
The verdict
NCT02680587, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Men with oligometastatic prostate cancer lesions will be randomized (1:2) to observation versus SBRT. The study will NOT be blinded. Within three weeks of the initial treatment planning, SBRT (1-5 fractions) will be administered.
Interventions
- RADIATION SBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-04-28 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02680587
The ClinicalTrials.gov registry entry for NCT02680587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SBRT is the first listed.
NCT02680587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02680587 about?
NCT02680587 is a clinical study titled "Stereotactic Body Radiation for Prostate Oligometastases". Men with oligometastatic prostate cancer lesions will be randomized (1:2) to observation versus SBRT. The study will NOT be blinded. Within three weeks of the initial treatment planning, SBRT (1-5 fractions) will be administered.
What is the current status of trial NCT02680587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-04-28. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT02680587?
The interventions under investigation include: SBRT (RADIATION).
Who is sponsoring clinical trial NCT02680587?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.